Michelle Mitchell: These findings from a study funded by Cancer Research UK (CRUK) mean we can be optimistic that treatment of neuroblastoma in the future will be kinder on children with this type of cancer, and improve their quality of life.
Michelle Mitchell shared a post by University of Cambridge on LinkedIn, adding:
“These findings from a study funded by Cancer Research UK (CRUK) mean we can be optimistic that treatment of neuroblastoma in the future will be kinder on children with this type of cancer, and improve their quality of life. I’m very proud of the work so far, and it was great to read the thoughts of Cancer Research UK’s Children’s and Young People’s Research Lead, Dr Laura Danielson, who’s featured in this article.”
Quoting University of Cambridge’s post:
“Neuroblastoma, a rare cancer that affects young children, is devastating and the treatments can be harsh.
But there’s light – thanks to some tadpoles, poetry, and scientists at Wellcome-MRC Cambridge Stem Cell Institute, improved treatments could soon be on their way.”
For details click here.
Source: Michelle Mitchell/LinkedIn and University of Cambridge/LinkedIn
Michelle Mitchell is the first female chief executive of Cancer Research UK (CRUK), the world’s leading charitable funder of cancer research. In 2021/22 the charity had an income of £668m, spent £443m on cancer research and had approximately 4,000 staff and over 30,000 volunteers. Before joining Cancer Research UK, Michelle was CEO of the MS Society for five years and a founding member of the Progressive MS Alliance: a global scientific and research joint venture and launched the STOP MS £100m appeal. Prior to that, she was Director General at Age UK, the UK’s largest older people’s charity where she worked for nearly a decade and was at the forefront of national debates on health, care and welfare. Mitchell was appointed Order of the British Empire (OBE) in the 2016 New Year Honours for services to Older People and the Voluntary Sector. She was named by Cranfield University as one of the 100 Women to Watch in 2018.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023